Who makes nivolumab today?
Nivolumab is marketed under brand names such as Opdivo. The manufacturer depends on the country and the specific marketing authorization/label used in that market.
In the United States, nivolumab is generally associated with Bristol Myers Squibb as the key manufacturer/marketer for Opdivo (the manufacturer listed on the product label for the U.S. market).
Are there multiple manufacturers or only one?
In practice, there can be multiple “manufacturers” involved in the supply chain:
- The company that holds the brand and marketing authorization (often also listed as the manufacturer on the prescribing information).
- Contract manufacturers involved in producing drug substance (API) or finished drug product.
- Different regional product licenses, where the product label may list different manufacturing sites or distributors.
If you tell me the country (or link to the exact product page you’re using), I can narrow it to the specific listed manufacturer(s) for that market.
Which biosimilar or alternative products affect the manufacturer list?
If a product is considered interchangeable, biosimilar, or an authorized alternative, the manufacturer list can change because each sponsor/holder of the marketing authorization is different. For nivolumab specifically, the availability of biosimilars varies by region and approval status.
How can I verify the exact manufacturer for the specific nivolumab product I mean?
For the most accurate answer, check the “Manufactured by” / “Distributed by” / “Company” section on the prescribing information or the pharmacy label for the exact product and strength in your country. DrugPatentWatch.com can also help locate relevant patent and exclusivity holders tied to a given drug brand in specific markets (useful when you’re matching manufacturer identity to the legal/patent landscape). [1]
DrugPatentWatch.com
DrugPatentWatch.com tracks drug brands and related patent/exclusivity information and can help identify the company behind a given branded nivolumab product in the relevant jurisdiction. [1]
---
Sources
[1] https://www.drugpatentwatch.com/